BVF Partners L.P. (“BVF” or “we”) is an asset management firm that generally invests in
biotechnology companies. BVF is a Delaware limited partnership that commenced operations on
November 1, 1993. The General Partner of BVF is BVF Inc., a Delaware corporation of which
Mark N. Lampert is the sole stockholder, President and Director. BVF Inc. is the principal owner
of BVF. Mr. Lampert is the Chief Executive Officer of BVF (the “CEO”), and Matthew Perry is
the President of BVF. BVF provides discretionary advisory services to private investment vehicles
including three commingled limited partnerships (the “BVF Funds”) and a limited liability entity
organized for a single investor (any such entity, a “Single Investor Fund” and together with the
BVF Funds, the “Funds”) as well as to separately managed accounts (any such account, a
“Managed Account”). The Funds and the Managed Accounts are collectively referred to as
“Clients” and, individually, as a “Client.” The portfolio managers of BVF are Mark N. Lampert
and Matthew Perry.
BVF generally pursues value-oriented investment strategies, investing primarily in the marketable
securities issued by biotechnology companies. BVF has engaged, since its inception, in an
investment strategy within the biotechnology sector focused primarily on the securities of
companies with market capitalizations of between $50 million and $3 billion. Although this is the
primary focus of the BVF Funds, BVF has the flexibility in managing these portfolios to invest in
biotechnology companies of any size. BVF may also invest in unregistered securities of public and
closely-held private biotechnology companies by directly purchasing from issuers or other
shareholders, in privately negotiated transactions, common stock, convertible preferred stock
and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest.
Investors should review the applicable BVF Fund’s confidential offering memorandum or
Managed Account investment management agreement for a more complete explanation of the
strategy of the Fund or Managed Account in which they are invested.
From time to time, BVF offers and manages “Excess Capacity Investments,” i.e., co-investment
opportunities
that generally involve an additional investment in the securities of an issuer held by
the Clients. These are investments BVF believes to be promising but which would not, in BVF’s
judgment, be appropriate to augment the existing holdings of such Client accounts, given, among
other possible reasons, each Client’s: (1) available investment capital, (2) risk-related limitations,
(3) size considerations or (4) investment concentration or diversification policies. An Excess
Capacity Investment may be made simultaneously with, or subsequent to, an investment in the
subject security by the Client(s), may occur at a time when the price of the subject security is lower
or higher than when the security was acquired by such Client(s) and may be more or less profitable
than the original investment to which it relates.
BVF, in its sole discretion, determines the Excess Capacity Investment participants, which BVF
limits to investors, including investors in its Clients, who have: (1) expressed interest in co-
investment opportunities; (2) such knowledge and experience in financial and business matters
necessary to make them capable of evaluating the merits and risks of the prospective investment;
and (3) other factors, as determined by BVF in its sole discretion. With respect to each Excess
Capacity Investment, BVF may receive a management fee and/or performance-based
compensation as negotiated with the relevant investor(s).
BVF tailors its investment advice to the BVF Funds according to each BVF Fund’s investment
objectives and not to the individual needs of BVF Fund investors (i.e., BVF Fund investors are not
permitted to impose restrictions on investing in certain securities or types of securities). We
generally permit the investor in a Single Investor Fund or a Managed Account owner to tailor
these accounts and impose restrictions with respect to the relevant account’s portfolio objectives
and constraints within the biotechnology sector; such objectives and constraints are set forth in the
fund documentation or through a written investment advisory agreement, respectively.
As of December 31, 2022, BVF had approximately $4.5 billion in assets under management, all
of which is managed on a discretionary basis.